MicroRNA-129 and -335 Promote Diabetic Wound Healing by Inhibiting Sp1-Mediated MMP-9 Expression

Diabetes. 2018 Aug;67(8):1627-1638. doi: 10.2337/db17-1238. Epub 2018 May 10.

Abstract

Diabetic wounds are recalcitrant to healing. However, the mechanism causing this dysfunction is not fully understood. High expression of matrix metalloproteinase-9 (MMP-9) is indicative of poor wound healing. In this study, we show that specificity protein-1 (Sp1), a regulator of MMP-9, binds directly to its promoter and enhances its expression. Additionally, we demonstrated that Sp1 is the direct target of two microRNAs (miRNAs), miR-129 and -335, which are significantly downregulated in diabetic skin tissues. In vitro experiments confirmed that miR-129 or -335 overexpression inhibits MMP-9 promoter activity and protein expression by targeting Sp1, whereas the inhibition of these miRNAs has the opposite effect. The beneficial role of miR-129 or miR-335 in diabetic wound healing was confirmed by the topical administration of miRNA agomirs in diabetic animals. This treatment downregulated Sp1-mediated MMP-9 expression, increased keratinocyte migration, and recovered skin thickness and collagen content. The combined treatment with miR-129 and miR-335 induced a synergistic effect on Sp1 repression and MMP-9 downregulation both in vitro and in vivo. This study demonstrates the regulatory mechanism of Sp1-mediated MMP-9 expression in diabetic wound healing and highlights the potential therapeutic benefits of miR-129 and -335 in delayed wound healing in diabetes.

Publication types

  • Research Support, Non-U.S. Gov't
  • Validation Study

MeSH terms

  • Administration, Cutaneous
  • Adult
  • Animals
  • Antagomirs / administration & dosage
  • Antagomirs / pharmacology
  • Antagomirs / therapeutic use
  • Cell Line
  • Cells, Cultured
  • Diabetic Foot / drug therapy
  • Diabetic Foot / metabolism*
  • Diabetic Foot / pathology
  • Diabetic Foot / therapy
  • Enzyme Induction / drug effects
  • Female
  • Humans
  • Infant, Newborn
  • Keratinocytes / cytology
  • Keratinocytes / drug effects
  • Keratinocytes / metabolism
  • Keratinocytes / pathology
  • Male
  • Matrix Metalloproteinase 9 / metabolism*
  • MicroRNAs / agonists
  • MicroRNAs / antagonists & inhibitors
  • MicroRNAs / metabolism*
  • Promoter Regions, Genetic / drug effects
  • RNA Interference
  • RNAi Therapeutics
  • Rats, Sprague-Dawley
  • Skin / drug effects
  • Skin / injuries*
  • Skin / metabolism
  • Skin / pathology
  • Sp1 Transcription Factor / antagonists & inhibitors
  • Sp1 Transcription Factor / genetics
  • Sp1 Transcription Factor / metabolism*
  • Up-Regulation / drug effects
  • Wound Healing* / drug effects

Substances

  • Antagomirs
  • MIRN335 microRNA, human
  • MicroRNAs
  • Mirn129 microRNA, human
  • Sp1 Transcription Factor
  • SP1 protein, human
  • MMP9 protein, human
  • Matrix Metalloproteinase 9